-
Global Biotechnology & Pharmaceutical Markets1 month agoAustralia starts probe into AI infiltration of Medicare
The infiltration of Australia's Medicare by an AI agent raises serious questions about patient privacy and the security of confidential pharma data.
-
Regulatory Intelligence & Drug Approvals1 month agoLilly’s rival to Novo’s new Awiqli insulin gets FDA approval
The FDA has approved Eli Lilly's once-weekly basal insulin product Onswik, setting up a market tussle with Novo's recently launched Awiqli.
-
Synthetic Biology, Genomics & Advanced Therapeutics1 month agoKyverna builds case for CAR-T in stiff person syndrome
Kyverna has data with miv-cel in stiff person syndrome that shows durable efficacy and safety and seems to sidestep issues flagged with other CAR-Ts.
-
Capital, M&A & Industry Strategy1 month agoLilly forges $3.35bn alliance with China’s InnoCare
Eli Lilly continues a busy period of deal-making with a five-project partnership with InnoCare that includes $100m in upfront and near-term payments.
-
Regulatory Intelligence & Drug Approvals1 month agoGrail cancer test gets lukewarm backing from FDA adcomm
FDA expert advisors voted in favour of Grail's Galleri blood test for detecting multiple cancers, but some expressed misgivings about its efficacy.
-
Capital, M&A & Industry Strategy1 month agoUK issues £45m funding call for research partnerships
The NIHR has revealed the first £45m in funding for projects that can bridge the translation gap in healthcare, focusing initially on community care.
-
Global Biotechnology & Pharmaceutical Markets1 month agoUK needs ‘clearer path for dementia diagnosis and treatment’
UK Prime Minister Andy Burnham, who lost his father to Alzheimer's last week, has been urged to implement a "cancer-style" reform of dementia care.
-
Capital, M&A & Industry Strategy1 month agoIambic files IPO after signing up AbbVie as new partner
In the space of a day, Iambic has filed an IPO, released the latest version of its AI platform, and signed a multi-year alliance with AbbVie.
-
Global Biotechnology & Pharmaceutical Markets1 month agoUK first country to launch CSL’s trivalent flu shot Aujemflu
CSL Seqirus' recently approved trivalent, cell-based influenza vaccine Aujemflu will be part of the UK's 2027/28 immunisation campaign.
-
Global Biotechnology & Pharmaceutical Markets1 month agoAdvocacy group pokes holes in Trump’s MFN pricing claims
Public Citizen says claims for the drug price savings that are being delivered by Trump's Most Favoured Nation deals with pharma are "a mirage."
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
